AbCellera Biologics Inc. Common Shares
Here’s whether AbCellera Biologics Inc. Common Shares (ABCL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); strong 1-year return of +67.8%. Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-1.42% over 10 days); RSI 80 — overbought, elevated pullback risk; rising volume on a downtrend (distribution, 1.16x avg). Currently 38.5% off its 52-week high. Score: -2/7.
ABCL is trading below its 200-day MA ($4.13) — a key warning sign the longer-term trend is under pressure. With an RSI of 79.8, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +67.8% compares to +35.1% for SPY (beat the market by 32.7%). The current 38.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.